6
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment?

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Gastroesophageal adenocarcinoma is relatively common in elderly patients as the incidence increases with age. However, the optimal treatment approach is not well established in this group of patients. The aim of this study is to review our experience for localized gastroesophageal adenocarcinoma in patients aged ≥80 years and to assess association between patient characteristics, clinical factors, and overall survival (OS) in order to optimize the therapeutic approaches for this population. Methods: Patients ≥80 years old treated for localized gastroesophageal adenocarcinoma were retrospectively analyzed. Survival curves were estimated using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards regression models were applied to assess the association between patient characteristics and OS. Factors that were significant in the multivariate model were included in the final reduced model. Results: 127 patients ≥80 years old, were included in this study with median age of 83 years. The median follow-up time was 3.2 years, and median OS was 2.5 years (95% CI: 2.0–3.1 years). Independent prognostic factors for OS were Eastern Cooperative Oncology Group (ECOG) performance status (PS) ( p = 0.003), baseline clinical stage ( p = 0.01), and surgery ( p = 0.001). ECOG PS, tumor location, baseline stage, tumor grade, and surgery were included in the final reduced model. Conclusion: Surgical treatment can improve survival in elderly patients. Therapeutic decisions should be based on the patients’ general condition rather that age alone.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          Oncology
          S. Karger AG
          0030-2414
          1423-0232
          2023
          March 2023
          21 November 2022
          : 101
          : 3
          : 153-158
          Affiliations
          [_a] aDepartment of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
          [_b] bDepartment of Medical Oncology, University of Crete, Heraklion, Greece
          [_c] cDepartment of Biostatistics, The University of Texas M.D. Anderson Cancer, Houston, Texas, USA
          [_d] dDepartment of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan
          [_e] eDepartment of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center M.D. Anderson Cancer Center, Houston, Texas, USA
          [_f] fDepartment of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
          [_g] gDepartment of Pharmacy Clinical Programs, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
          [_h] hDepartment of Gastroenterology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
          [_i] iDepartment of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
          [_j] jDepartment of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
          Author notes
          *Jaffer A. Ajani, jajani@mdanderson.org
          Author information
          https://orcid.org/0000-0002-3129-2259
          https://orcid.org/0000-0002-3516-0966
          https://orcid.org/0000-0002-0886-4618
          https://orcid.org/0000-0003-4466-1823
          https://orcid.org/0000-0002-7275-7008
          https://orcid.org/0000-0001-6740-3670
          Article
          525927 Oncology 2023;101:153–158
          10.1159/000525927
          36412619
          014471be-5924-4960-98c4-bfa5aaf20cb7
          © 2022 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

          History
          : 06 April 2022
          : 23 April 2022
          Page count
          Figures: 1, Tables: 3, Pages: 6
          Funding
          This research received no external funding.
          Categories
          Clinical Study

          Medicine
          Gastroesophageal adenocarcinoma,Chemoradiotherapy,Surgery,Prognosis,Survival,Medically fit,Elderly

          Comments

          Comment on this article